Akebia Therapeutics (AKBA) Return on Sales (2017 - 2026)

Akebia Therapeutics (AKBA) has 10 years of Return on Sales data on file, last reported at 0.0% in Q1 2026.

• Return on Sales for Q1 2026 came in at 0.0%, changed 0.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.0% (changed 0.0% YoY), and the FY2025 annual result was 0.0%, changed 0.0% from the prior year.
• Return on Sales improved to 0.0% in Q1 2026 per AKBA's latest filing, from 0.0% in the prior quarter.
• Over five years, Return on Sales peaked at 0.01% in Q2 2022 and troughed at 0.02% in Q1 2022.
• A 5-year average of 0.0% and a median of 0.0% in 2023 frame the typical range for Return on Sales.
• On a YoY basis, Return on Sales climbed as much as 2 bps in 2022 and fell as far as 1 bps in 2022.
• A 5-year view of Return on Sales shows it stood at 0.0% in 2022, then surged by 109 bps to 0.0% in 2023, then sank by 4589 bps to 0.0% in 2024, then jumped by 57 bps to 0.0% in 2025, then grew by 20 bps to 0.0% in 2026.
• Business Quant data shows AKBA's Return on Sales at 0.0% in Q1 2026, 0.0% in Q4 2025, and 0.0% in Q3 2025.